Skip to main
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 43%
Hold 14%
Sell 7%
Strong Sell 0%

Bulls say

Alkermes is well positioned for long-term growth with a robust portfolio of marketed drugs and a strong pipeline of potential therapies for neurodegenerative and CNS diseases. The company's lead clinical candidate, ALKS 2680, has shown promising results in Phase 2b trials and has the potential to have a broad label for multiple indications. Additionally, the recent updates on the safety and efficacy profile of ALKS 2680 at the SLEEP conference further solidify the drug's strong profile, leading to an increase in the peak share for NT2 and raising the probability of success for narcolepsy treatment.

Bears say

Alkermes is facing stiff competition in the biotechnology industry, with catalyst-rich updates from its competitors such as VIBRANCE-3 IH data, ALKS 7190 Ph 1bin ADHD, and Cleminorexton's ongoing study for NT1/NT2. Despite potentially being second to market in NT1, management remains confident in its position, but this may indicate potential challenges in garnering physician and patient support for its products. Additionally, purchasing active drug products may strain Alkermes' finances and resources, leading to a negative outlook on the company's stock.

Alkermes (ALKS) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 14 analysts, Alkermes (ALKS) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.